The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

EDITORIAL

PCI in TAVI patients: who, why and when?

EuroIntervention 2018;14:e1160-e1162 published online e-edition December 2018. DOI: 10.4244/EIJV14I11A209

1. Cardiovascular Department, King’s College London, St Thomas’ Hospital, London, United Kingdom; 2. Cardiovascular Department, St Thomas’ Hospital, Guy’s and St Thomas’ Hospital NHS Foundation Trust, London, United Kingdom


In the last decade, transcatheter aortic valve implantation (TAVI) has become an important alternative to surgical aortic valve replacement (sAVR) for those at intermediate and high surgical risk. The efficacy and safety of TAVI have been demonstrated in several randomised trials1-3. As a result there has been rapid growth in TAVI with more than 300,000 procedures performed worldwide. Patient selection and evaluation is best achieved by a Heart Team approach4. This shared decision making includes assessment of symptom severity and comorbidities4. Observational data suggest that coronary artery disease (CAD) co-exists in up to 60% of cases5. This high prevalence can ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article

Percutaneous revascularisation of chronic occluded coronaries – availability of the retrograde approach increases technical success and the quality of life despite more frequent complications